Report of 5 novel mutations of the α-L-iduronidase gene and comparison of Korean mutations in relation with those of Japan or China in patients with mucopolysaccharidosis I by unknown
RESEARCH ARTICLE Open Access
Report of 5 novel mutations of the α-L-
iduronidase gene and comparison of
Korean mutations in relation with those
of Japan or China in patients with
mucopolysaccharidosis I
Min Jung Kwak1, Rimm Huh2, Jinsup Kim2, Hyung-Doo Park3, Sung Yoon Cho2 and Dong-Kyu Jin2*
Abstract
Background: Mucopolysaccharidosis I (MPS I) is an autosomal recessive lysosomal storage disorder caused by a
lack of the lysosomal enzyme α-L-iduronidase (IDUA). To date, more than 200 IDUA mutations have been reported.
However, only a few types of mutations are recurrent and the frequencies of mutations differ from country to
country.
Methods: We performed the IDUA mutation analysis in seven patients who were biochemically diagnosed with
MPS I in the Department of Pediatrics, Samsung Medical Center, from 2009 to 2014. Here, we describe the results of
the IDUA mutation analysis in seven patients with MPS I and the IDUA mutational spectrum in Korean patients with
MPS I, including previous data.
Results: The IDUA mutations were found in all 14 alleles of 7 patients, and 11 kinds of IDUA mutations were identified.
The detected mutations were five missense mutations (p.A79V, p.L346R, p.T388K, p.P496R, and p.C577Y), two nonsense
mutations (p.Y618* and p.R628*), two deletions (c.683delC and c.1591delC), one splice site mutation (c.972+1G>A), and
one duplication (c.613_617dup). Among these, p.T388K, p.C577Y, c.683delC, c.1591delC, and c.972+1G>A were novel
mutations that have not previously been reported. After taking everything into consideration, including IDUA mutation
analysis of the previously reported 10 unrelated Korean patients with MPS I, p.L346R and c.704ins5 were most
commonly found in Korean patients with MPS I. However, p.W402* and p.Q70*, which have mainly been found in
Caucasian patients, were not found.
Conclusion: As a result, p.L346R and c.704ins5, which were the most common in Korea, which is geographically situated
midway between China and Japan, were some of the most common mutations in China and Japan, respectively. These
results are especially worthy of notice.
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Background
Mucopolysaccharidosis I (MPS I) is an autosomal recessive
lysosomal storage disorder caused by a lack of the lyso-
somal enzyme α-L-iduronidase (IDUA) [1]. IDUA is an en-
zyme involved in the metabolism of glycosaminoglycans
(GAGs). In the case of IDUA deficiency, heparan sulfate
and dermatan sulfate, which are types of GAGs, accumulate
in various tissues [2]. MPS I is divided into three pheno-
types clinically. The most severe phenotype is Hurler syn-
drome (MPS IH; MIM#607914), and the mildest
phenotype is Scheie syndrome (MPS IS; MIM#607016).
The intermediate phenotype is Hurler-Scheie syndrome
(MPS IH/S; MIM#607015) [1, 3]. The α-L-iduronidase-cod-
ing gene is IDUA, which is located in chromosome 4p16.3
[4]. To date, more than 200 IDUA mutations have been re-
ported [5]. Of these, missense/nonsense mutations have the
highest rates (58 %), followed by splice site mutations
(15.9 %), deletions (14 %), and insertions (7.3 %) [5]. The
authors first reported IDUA mutations in 10 unrelated Ko-
rean patients with MPS I in Korea in 2004 [6]. After that,
seven patients with MPS I were newly diagnosed, and five
novel mutations were confirmed through the IDUA muta-
tion analysis in Korea. Thus, the authors report the results
of IDUA mutations in seven patients and analyzed the




Seven patients who were diagnosed with MPS I through
IDUA mutation analysis in the Department of Pediatrics,
Samsung Medical Center, from 2009 to 2014 were se-
lected as study subjects in this study. All of these pa-
tients were biochemically diagnosed with MPS I because
they showed an increase in urinary GAGs and a reduc-
tion in IDUA activity in the leukocytes. The urinary
GAG levels and IDUA activity for each patient are
shown in the Additional file 1: Table S1. All seven pa-
tients were unrelated. Depending on the severity of the
patients’ clinical symptoms, they were classified as hav-
ing Hurler, Hurler-Scheie, or Scheie syndrome [1]. The
clinical characteristics of patients are shown in the Add-
itional file 1: Table S2. A written informed consent was
obtained from each patient or responsible family mem-
ber. Two patients showed homozygosity for one variant
in the IDUA mutation analysis. Therefore, we performed
array comparative genomic hybridization (CGH) to ex-
clude large deletion in these patients.
Molecular analysis
Human genomic DNA was extracted from white blood
cells using a Wizard genomic DNA purification kit (Pro-
mega, Madison, WI). All exons and the flanking regions of
the IDUA gene were amplified by polymerase chain
reaction (PCR) using primers designed by the authors (se-
quences available upon request) with a thermal cycler
(Model 970; Applied Biosystems, Foster City, CA). Direct
sequencing of the DNA was performed using the ABI
Prism 3100 Genetic Analyzer (Applied Biosystems) with
the BigDye Terminator Cycle Sequencing-Ready Reaction
Kit (Applied Biosystems). Nucleotides were numbered from
the first adenine of the ATG translation initiation codon in
the IDUA cDNA Reference Sequence NM_000203.3.
Array CGH
Array Affymetrix CytoScan 750K Array Genomic DNA
was extracted from peripheral blood leukocytes using a
QIAamp blood mini kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer’s instructions. The micro-
array assay was performed according to the manufacturer’s
protocols (Affymetrix Inc., Santa Clara, CA) [7]. Affymetrix
CEL files were analyzed using the Affymetrix Chromosome
Analysis Suite (CHAS) version 1.2.2. The reference model
file was provided by Affymetrix. The quality control (QC)
parameters used in our analyses and their definitions and
values, which were recommended by Affymetrix, were as
follows: Single nucleotide polymorphism quality control
(SNPQC: How well the A and B allele can be resolved) ≥15,
median of the absolute values of all pairwise differences
(MAPD: How similar the signal distribution of the sample
is relative to the reference model file) ≤0.25, and waviness-
SD (a global measure of variation of microarray probes that
is insensitive to short-range variation and focuses on long-
range variation) ≤0.12.
Results
The IDUA mutations of all 14 alleles were identified in a
total of seven patients. The genotypes and clinical phe-
notypes of seven patients are shown in Table 1. In this
study, a total of 11 IDUA mutations—that is, five mis-
sense mutations (p.A79V, p.L346R, p.T388K, p.P496R,
and p.C577Y), two nonsense mutations (p.Y618* and
p.R628*), two deletions (c.683delC and c.1591delC), one
splice site mutation (c.972+1G>A), and one duplication
(c.613_617dup) were identified. Among these, p.T388K,
p.C577Y, c.683delC, c.1591delC, and c.972+1G>A were
variations that had not been reported previously. These
five variations were considered novel mutations because
they were not observed in an in-house exome database
(n = 192 individuals). In addition, array CGH was per-
formed in two patients (patient two and patient seven in
Table 1) with the homozygosity for one variant to ex-
clude large deletion. The patient two who had a homo-
zygosity for p.T388K showed a loss of heterozygosity of
chromosome four. This means the patient two had uni-
parental disomy of p.T388K mutation in the IDUA gene.
The patient seven who had a homozygosity for p.L346R
showed a normal result in the array CGH.
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No one had the same genotype in the seven patients.
The homozygosity for p.T388K showed the phenotype of
Hurler-Scheie syndrome, and that for p.L346R showed that
of Scheie syndrome. The IDUA mutations of 10 Korean
patients with MPS I that have been previously reported are
also shown in Table 1. The results of both this study and
the previous study were analyzed together. IDUA mutation
analysis was performed in a total of 17 unrelated Korean
patients with MPS I, and IDUA mutations were identified
in 29 alleles. There were a total of 16 types of identified
IDUA mutations as follows: seven missense mutations
(p.A79V, p.A89W, p.P228Q, p.L346R, p.T388K, p.P496R,
and p.C577Y), three nonsense mutations (p.S534*, p.Y618*,
and p.R628*), three deletions (c.193delT, c.683delC, and
c.1591delC), one splice site mutation (c.972+1G>A), one
duplication (c.613_617dup), and one insertion (c.704ins5).
According to the allelic frequency, among a total of 29 al-
leles, eight were p.L346R (27.6 %), four were c.704ins5
(13.8 %), two were p.Y618* (6.9 %), and two were
c.613_617dup (6.9 %). Thus, p.L346R and c.704ins5 muta-
tions accounted for 41.4 % of the entire mutant IDUA al-
leles in Korean patients with MPS I.
Discussion
This study includes data that shows all of the IDUA muta-
tion results of Korean patients with MPS I to the present.
Sixteen kinds of mutations were confirmed in 17 patients,
and the variety of IDUA mutations in MPS I patients
could be confirmed. Only p.L346R, c.704ins5, p.Y618*,
and c.613_617dup mutations were recurrent mutations,
and other mutations were identified only in individual pa-
tients. Among these, p.L346R and c.704ins5 accounted for
27.6 and 13.8 %, respectively, in 29 mutant alleles, which
accounted for 41.4 % of mutant IDUA alleles in Korean
patients with MPS I. In particular, three patients showed
the same genotype in a total of 17 patients, all of them
had heterozygosity for p.L346R and c.704ins5, and they
showed the phenotype of Hurler syndrome.
p.L346R has an especially high frequency of mutations
in China. Among the mutant IDUA alleles of 57 Chinese
patients with MPS I, p.A79V accounted for 16.7 % (19/
114) and p.L346R accounted for 12.3 % (14/114). These
two were most commonly found in Chinese patients
with MPS I (Table 2) [8]. Among 57 patients, all three
patients who had homozygosity for p.L346R showed the
phenotype of Hurler-Scheie syndrome. Thus, it is con-
sidered that p.L346R had residual IDUA activity. In this
study, only one patient had homozygosity for p.L346R
and showed the phenotype of Scheie syndrome. Thus, it
is thought that racial difference and polymorphism af-
fected the expression of the mutation.
c.704ins5 is a mutation that was found only in Japanese
patients before IDUA mutations in Korean patients with
MPS I were reported [9]. In one study aimed at 19 patients,
p.R89Q accounted for 24 % (9/38) and c.704ins5 accounted
for 18 % (7/38) among mutant alleles. Thus, these two are
the most common mutations in Japanese patients with
MPS I (Table 2). Patients who had homozygosity for
c.704ins5 were associated with Hurler syndrome, and pa-
tients who had homozygosity for p.R89Q were associated
Table 1 Clinical phenotypes and genotypes in 17 unrelated Korean MPS I patients
Pt. Phenotype Allele 1 Allele 2 Ref.
1 H c.613_617dup (p.E207Afs*29) c.683delC (p.P228Hfs*6) This report
2 H-S c.1163C>A (p.T388K) c.1163C>A (p.T388K) This report
3 H-S c.613_617dup (p.E207Afs*29) c.1591delC (p.R531Gfs*29) This report
4 H-S c.236C>T (p.A79V) c.1882C>T (p.R628*) This report
5 H-S c.972+1G>A c.1730G>A (p.C577Y) This report
6 H-S c.1487C>G (p.P496R) c.1854C>A (p.Y618*) This report
7 S c.1037T>G (p.L346R) c.1037T>G (p.L346R) This report
8 H ? c.1037T>G (p.L346R) Ref#6
9 H c.704ins5 (p.W235Cfs*84) c.1037T>G (p.L346R) Ref#6
10 H c.704ins5 (p.W235Cfs*84) c.1854C>A (p.Y618*) Ref#6
11 H c.704ins5 (p.W235Cfs*84) c.1037T>G (p.L346R) Ref#6
12 H c.704ins5 (p.W235Cfs*84) c.1037T>G (p.L346R) Ref#6
13 H ? c. 193delT Ref#6
14 H-S ? c.1037T>G (p.L346R) Ref#6
15 H-S ? c.1037T>G (p.L346R) Ref#6
16 S ? c.683C>A (p.P228Q) Ref#6
17 S c.265C>T (p.A89W) c.1601C>A (p.S534*) Ref#6
H Hurler syndrome, H-S Hurler-Scheie syndrome, S Scheie syndrome, Pt. patient, Ref. reference; Novel mutations are in bold., ? not yet detected
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with Scheie syndrome. Additionally, those who had hetero-
zygosity for c.704ins5 and p.R89Q were associated with
Hurler-Scheie syndrome [9]. In this study, there were four
patients who had heterozygosity for c.704ins5 and other
mutations. All of them showed the phenotype of Hurler
syndrome, so it is thought that the c.704ins5 mutation is as-
sociated with a severe phenotype. It is interesting that
p.L346R and c.704ins5, which are the most common muta-
tions in Korea, which is situated midway between China
and Japan, are the most common mutations in China and
Japan, respectively. p.A79V, which is common in China,
was found in one Korean patient with MPS I. p.R89Q,
which is common in Japan, was not found in Korean pa-
tients with MPS I. These results indicate that the popula-
tion in these three countries started from one population
and the difference in the types and frequency of the com-
mon mutations in these three countries was because of the
founder effect. However, a haplotype analysis for their
population might be needed in order to prove this.
To date, more than 200 IDUA mutations have been re-
ported to the Human Gene Mutation Database [5]. Most
mutations occur only within the family. There are a few
types of mutations with a high frequency globally and by
regional group [10–14]. In Europe, p.W402* and p.Q70*,
which are two nonsense mutations, accounted for 37 %
(34/92) and 35 % (32/92), respectively, of mutant alleles
and are most commonly found [11]. There was a differ-
ence in the frequency of each country. p.W402* was the
most common, with 38.8 % (14/36) in Spain [10], and
p.Q70* was the most common, with 39 % (18/46) and
62 % (21/34), respectively, in Poland and Scandinavia [10,
11]. Additionally, p.W402* and p.Q70* accounted for 39 %
(17/44) and 30 % (13/44), respectively, in the United States
and showed the highest frequency [15]. p.W402* and
p.Q70* created a premature stop codon and showed a se-
vere phenotype in homozygotes [11, 16, 17]. p.W402* and
p.Q70*, which are common in Caucasian patients, were
not found in Korean patients with MPS I. There have also
been no reports of these mutations in China and Japan.
Conclusions
In this study, the IDUA mutational spectrum of Korean
patients with MPS I was analyzed, and it was found that
p.L346R and c.704ins5 were common mutations in Korea.
Furthermore, five novel mutations that were not reported
before, p.T388K, p.C577Y, c.683delC, c.1591delC, and
c.972+1G>A, were newly discovered. A variety of IDUA
mutations were able to be identified. It is thought that if
the IDUA mutation analysis results of newly diagnosed
MPS I patients are accumulated, they would help to ascer-
tain the prognosis of the patients by revealing the associ-
ation between genotype and phenotype and would be very
helpful for prenatal diagnosis.
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MPS I. (DOCX 15 kb)
Abbreviations
CGH, comparative genomic hybridization; GAGs, glycosaminoglycans; IDUA,
α-L-iduronidase; MPS I, mucopolysaccharidosis I; MPS IH, Hurler syndrome;
MPS IH/S, Hurler-Scheie syndrome; MPS IS, Scheie syndrome
Acknowledgments
The authors would like to thank all patients.
Funding
This study was supported by grants from Samsung Medical Center [grant
#GFO 2160061] and Samsung Bio Research Institute [SMO1131471].
Availability of data and materials
The authors declare that the data supporting the findings of this study are
available within the article and its supplementary information files.
Authors’ contributions
MK, SC and DJ designed the study. MK drafted the manuscript. HP carried
out the genetic analysis. SC and DJ helped to draft the manuscript. All
authors were involved in analysing and interpreting data. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
A written informed consent for publication was obtained from each patient
or responsible family member.
Ethics approval and consent to participate
This study was made after obtaining appropriate informed consent, and the
Institutional Review Board (IRB) at Samsung Medical Center approved this
study (IRB number:2015-05-025-002).
Author details
1Department of Pediatrics, Pusan National University Hospital, Pusan National
University School of Medicine, 179 Gudeok-roSeo-gu, Busan 602-739, Korea.
2Department of Pediatrics, Samsung Medical Center, Sungkyunkwan
University School of Medicine, 81 Irwon-roGangnam-gu, Seoul 135-710,
Korea. 3Laboratory Medicine & Genetics, Samsung Medical Center,
Sungkyunkwan University School of Medicine, 81 Irwon-roGangnam-gu,
Seoul 135-710, Korea.
Received: 7 September 2015 Accepted: 29 July 2016
References
1. McKusick VA, Howell RR, Hussels IE, Neufeld EF, Stevenson RE. Allelism, non-
allelism, and genetic compounds among the mucopolysaccharidoses.
Lancet. 1972;1:993–6.
2. Hopwood JJ, Morris CP. The mucopolysaccharidoses. Diagnosis, molecular
genetics and treatment. Mol Biol Med. 1990;7:381–404.
Table 2 Comparison of the common IDUA mutations in Korea,
China, and Japan




Korea p.L346R (27.6 %, 8/29) c.704ins5 (13.8 %, 4/29)
Chinab p.A79V (16.7 %, 19/114) p.L346R (12.3 %, 14/114)
Japanc p.R89Q (24 %, 9/38) c.704ins5 (18 %, 7/38)
a, allelic frequency; b[8]; c[9]
Kwak et al. BMC Medical Genetics  (2016) 17:58 Page 4 of 5
3. Beesley CE, Meaney CA, Greenland G, Adams V, Vellodi A, Young EP, et al.
Mutational analysis of 85 mucopolysaccharidosis type I families: frequency
of known mutations, identification of 17 novel mutations and in vitro
expression of missense mutations. Hum Genet. 2001;109:503–11.
4. Scott HS, Ashton LJ, Eyre HJ, Baker E, Brooks DA, Callen DF, et al.
Chromosomal localization of the human alpha-L-iduronidase gene (IDUA)
to 4p16.3. Am J Hum Genet. 1990;47:802–7.
5. The Human Gene Mutation Database. Cardiff University. 2015. http://www.
hgmd.org. Accessed 30 July 2015.
6. Lee IJ, Hwang SH, Jeon BH, Song SM, Kim JS, Paik KH, et al. Mutational
analysis of the alpha-L-iduronidase gene in 10 unrelated Korean type I
mucopolysaccharidosis patients: Identification of four novel mutations. Clin
Genet. 2004;66:575–6.
7. Affymetrix, Inc. 2015. http://www.affymetrix.com. Accessed 30 July 2015.
8. Wang X, Zhang W, Shi H, Qiu Z, Meng Y, Yao F, et al.
Mucopolysaccharidosis I mutations in Chinese patients: identification of 27
novel mutations and 6 cases involving prenatal diagnosis. Clin Genet. 2012;
81:443–52.
9. Yamagishi A, Tomatsu S, Fukuda S, Uchiyama A, Shimozawa N, Suzuki Y, et
al. Mucopolysaccharidosis type I: identification of common mutations that
cause Hurler and Scheie syndromes in Japanese populations. Hum Mutat.
1996;7:23–9.
10. Bertola F, Filocamo M, Casati G, Mort M, Rosano C, Tylki-Szymanska A, et al.
IDUA mutational profiling of a cohort of 102 European patients with
mucopolysaccharidosis type I: identification and characterization of 35 novel
alpha-L-iduronidase (IDUA) alleles. Hum Mutat. 2011;32:E2189–210.
11. Bunge S, Kleijer WJ, Steglich C, Beck M, Zuther C, Morris CP, et al.
Mucopolysaccharidosis type I: identification of 8 novel mutations and
determination of the frequency of the two common alpha-L-iduronidase
mutations (W402X and Q70X) among European patients. Hum Mol Genet.
1994;3:861–6.
12. Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ. Molecular
genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological
implications. Hum Mutat. 1995;6:288–302.
13. Vazna A, Beesley C, Berna L, Stolnaja L, Myskova H, Bouckova M, et al.
Mucopolysaccharidosis type I in 21 Czech and Slovak patients: mutation
analysis suggests a functional importance of C-terminus of the IDUA
protein. Am J Med Genet A. 2009;149A:965–74.
14. Gatti R, DiNatale P, Villani GR, Filocamo M, Muller V, Guo XH, et al. Mutations
among Italian mucopolysaccharidosis type I patients. J Inherit Metab Dis.
1997;20:803–6.
15. Li P, Wood T, Thompson JN. Diversity of mutations and distribution of
single nucleotide polymorphic alleles in the human alpha-L-iduronidase
(IDUA) gene. Genet Med. 2002;4:420–6.
16. Scott HS, Litjens T, Hopwood JJ, Morris CP. A common mutation for
mucopolysaccharidosis type I associated with a severe Hurler syndrome
phenotype. Hum Mutat. 1992;1:103–8.
17. Scott HS, Litjens T, Nelson PV, Brooks DA, Hopwood JJ, Morris CP. alpha-L-
iduronidase mutations (Q70X and P533R) associate with a severe Hurler
phenotype. Hum Mutat. 1992;1:333–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kwak et al. BMC Medical Genetics  (2016) 17:58 Page 5 of 5
